Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Rectal Neoplasms 1Rare Diseases 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Brain Neoplasms 1Astrocytoma 1Adrenocortical Carcinoma 1

Interventions

Melphalan 3sargramostim 1romidepsin 1montanide ISA 51 1keyhole-limpet hemocyanin 1detox adjuvant 1Ursodeoxycholic Acid 1Thalidomide 1Streptozocin 1Mercaptopurine 1Leucovorin 1Interleukin-2 1Floxuridine 1FANG vaccine 1Docetaxel 1Celecoxib 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Genetic Diseases, Inborn × Streptozocin × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡